Special channel feed – Endpoints News

SIGN UP

Special channel feed

Special report: Twenty extraordinary women in biopharma R&D who worked their way to the top

3 years ago

The $102B club: The top 15 R&D spenders in the global biopharma business — 2019 edition

3 years ago

The top 10 pipeline blowups, setbacks and snafus for H1 2019

4 years ago

Biotech execs predict big M&A deals ahead as mood shifts in wake of a 2018 hangover — Endpoints 100

4 years ago

The top 10 pipeline blowups, setbacks and snafus for H2 2018

4 years ago

The 2018 breakdown on a chart-topping set of new drug approvals — and the 5 big things we learned from it

4 years ago

The top 10 stories from Endpoints News in 2018

4 years ago

What do Martin Shkreli, Gilead and Takeda have in common? They all figure prominently in the new top-20 list of the world’s most expensive drugs

4 years ago

A go-go FDA is poised to break the all-time record on new drug approvals. Is this the new standard for biopharma success?

4 years ago

Global reach: The top 25 biopharma companies in the world

5 years ago

The biotech mood at the halfway mark of 2018? Boisterous, focusing more attention on China and looking for accelerated progress

5 years ago

Who are the most productive drug developers in biopharma? Our top-20 list has lots of surprises

5 years ago

Top 10 pipeline blowups, setbacks and snafus in H1 2018

5 years ago

12 top China VCs you need to know who are making a transpacific splash (Part 2)

5 years ago

The under-40s: How does the next generation of biopharma executives view the future?

5 years ago

Elephants can't jump? IDEA's Mike Rea says some Big Pharma players are crushing old beliefs

5 years ago

12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you

5 years ago

The good, the bad and the ugly for the top 15 spenders in the global drug R&D business: 2018

5 years ago

Top 10 pipeline blowups, setbacks and snafus in H2 2017

5 years ago

Where the money is: Top 100 VCs investing in US biotechs during 2017

5 years ago

Video: How many PD-1/L1 drugs do we need? Where is immunotherapy headed? Watch Jay Bradner, Hervé Hoppenot, Ellen Sigal, David Berman, Gideon Blumenthal, and Aiman Shalabi discuss with Endpoints at #JPM18

5 years ago

The Endpoints 11: A group of disruptive upstarts on a do-or-die mission to launch new meds

5 years ago

The class of 2017's winners and losers: A year of 'nonstop scientific achievements' raises troubling issues

5 years ago

Analysts’ top 10 biotech takeover targets are concentrated in two key areas

5 years ago

First page Previous page 123 Next page Last page